Physician experiences in management of COVID‐19‐associated coagulopathy in pregnancy: Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis

Godoy, 2020, Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID‐19, CMAJ, 192, E1156, 10.1503/cmaj.201240 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 Iba, 2021, Proposal of the definition for COVID‐19‐associated coagulopathy, J Clin Med, 10, 191, 10.3390/jcm10020191 Malinowski, 2020, COVID‐19 susceptibility in pregnancy: immune/inflammatory considerations, the role of placental ACE‐2 and research considerations, Reprod Biol, 20, 568, 10.1016/j.repbio.2020.10.005 Kadir, 2020, COVID‐19 coagulopathy in pregnancy: critical review, preliminary recommendations, and ISTH registry—communication from the ISTH SSC for Women’s Health, J Thromb Haemost, 18, 3086, 10.1111/jth.15072 Goshua, 2020, Endotheliopathy in COVID‐19‐associated coagulopathy: evidence from a single‐centre, cross‐sectional study, Lancet Haematol, 7, e575, 10.1016/S2352-3026(20)30216-7 Nazy, 2020, Platelet activating immune complexes identified in COVID‐19 associated coagulopathy, medRxiv Althaus K, Marini I, Zlamal J et al. Severe COVID‐19 infection is associated with increased antibody‐mediated platelet apoptosis [Internet]. medRxiv. http://medrxiv.org/lookup/doi/10.1101/2020.09.03.20187286. Accessed July 26, 2021. Marik, 2008, Venous thromboembolic disease and pregnancy, N Engl J Med, 359, 2025, 10.1056/NEJMra0707993 Connors, 2020, COVID‐19 and its implications for thrombosis and anticoagulation, Blood, 135, 2033, 10.1182/blood.2020006000 The REMAP‐CAP, ACTIV‐4a, ATTACC Investigators, Zarychanski R. Therapeutic anticoagulation in critically Ill patients with Covid‐19 – preliminary report. medRxiv. https://www.medrxiv.org/content/10.1101/2021.03.10.21252749v1. Accessed July 26, 2021. Lopes, 2021, Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID‐19 and elevated D‐dimer concentration (ACTION): an open‐label, multicentre, randomised, controlled trial, Lancet, 397, 2253, 10.1016/S0140-6736(21)01203-4 LaCourse, 2020, Importance of inclusion of pregnant and breastfeeding women in COVID‐19 therapeutic trials, Clin Infect Dis, 71, 879, 10.1093/cid/ciaa444 Malinowski, 2020, Excluding pregnancy from COVID‐19 trials: protection from harm or the harm of protection?, CMAJ, 192, E634, 10.1503/cmaj.75807 Kim, 2020, Comparative efficacy and safety of pharmacological interventions for the treatment of COVID‐19: A systematic review and network meta‐analysis, PLoS Med, 17, 10.1371/journal.pmed.1003501 Zhang, 2020, D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19, J Thromb Haemost JTH, 18, 1324, 10.1111/jth.14859 Harris, 2009, Research electronic data capture (REDCap)–a metadata‐driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, 42, 377, 10.1016/j.jbi.2008.08.010 The REDCap consortium: Building an international community of software platform partners ‐ PubMed [Internet]. https://pubmed.ncbi.nlm.nih.gov/31078660/. Accessed February 15, 2021. Zambrano, 2020, Update: characteristics of symptomatic women of reproductive age with laboratory‐confirmed SARS‐CoV‐2 infection by pregnancy status — United States, January 22–October 3, 2020, MMWR Morb Mortal Wkly Rep [Internet], 69, 1641, 10.15585/mmwr.mm6944e3 McClymont, 2021, Canadian surveillance of COVID‐19 in pregnancy (CANCOVID‐Preg): a rapidly coordinated national response using established regional infrastructures, J Obstet Gynaecol Can, 43, 165, 10.1016/j.jogc.2020.10.005 CDC. COVID data tracker [Internet]. Centers for disease control and prevention. https://covid.cdc.gov/covid‐data‐tracker. Accessed April 6, 2021. Yang, 2020, Thrombocytopenia and its association with mortality in patients with COVID‐19, J Thromb Haemost JTH, 18, 1469, 10.1111/jth.14848 Castaman, 2013, Changes of von Willebrand factor during pregnancy in Women with and without von Willebrand disease, Mediterr J Hematol Infect Dis [Internet], 5 Malas, 2020, Thromboembolism risk of COVID‐19 is high and associated with a higher risk of mortality: a systematic review and meta‐analysis, EClinicalMedicine [Internet], 29, 100639, 10.1016/j.eclinm.2020.100639 Turan, 2020, Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS‐CoV‐2 infection among hospitalized pregnant women: a systematic review, Int J Gynecol Obstet, 151, 7, 10.1002/ijgo.13329 Servante, 2021, Haemostatic and thrombo‐embolic complications in pregnant women with COVID‐19: a systematic review and critical analysis, BMC Pregnancy Childbirth, 21, 108, 10.1186/s12884-021-03568-0 Vlachodimitropoulou Koumoutsea, 2020, COVID‐19 and acute coagulopathy in pregnancy, J Thromb Haemost, 18, 1648, 10.1111/jth.14856 Charbit, 2007, The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage, J Thromb Haemost, 5, 266, 10.1111/j.1538-7836.2007.02297.x Zhang, 2020, Endothelial dysfunction contributes to COVID‐19‐associated vascular inflammation and coagulopathy, Rev Cardiovasc Med, 21, 315, 10.31083/j.rcm.2020.03.126 2021, Dexamethasone in hospitalized patients with Covid‐19, N Engl J Med, 384, 693, 10.1056/NEJMoa2021436 2021, Tocilizumab in patients admitted to hospital with COVID‐19 (RECOVERY): a randomised, controlled, open‐label, platform trial, The Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 Taylor, 2021, Inclusion of pregnant women in COVID‐19 treatment trials: a review and global call to action, Lancet Glob Health, 9, e366, 10.1016/S2214-109X(20)30484-8 ASH Guidelines on Use of Anticoagulation in Patients with COVID‐19 ‐ Hematology.org [Internet]. https://www.hematology.org:443/education/clinicians/guidelines‐and‐quality‐care/clinical‐practice‐guidelines/venous‐thromboembolism‐guidelines/ash‐guidelines‐on‐use‐of‐anticoagulation‐in‐patients‐with‐covid‐19. Accessed April 6, 2021.